European research networks to facilitate drug research in children

Paediatric drug development faces several barriers. These include fragmentation of stakeholders and inconsistent processes during the conduct of research. This review summarises recent efforts to overcome these barriers in Europe. Two exemplar initiatives are described. The European Paediatric Translational Research Infrastructure facilitates preclinical research and other work that underpins clinical trials. conect4children facilitates the design and implementation of clinical trials. Both these initiatives listen to the voices of children and their advocates. Coordination of research needs specific effort that supplements work on science, resources and the policy context.

[1]  K. Norga,et al.  Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. , 2020, European journal of cancer.

[2]  Annalisa Landi,et al.  Survey by TEDDY European Network of Excellence for Paediatric Clinical Research demonstrates potential for Europe‐wide trials , 2020, Acta paediatrica.

[3]  B. Nafria,et al.  Children’s views on taking medicines and participating in clinical trials , 2019, Archives of Disease in Childhood.

[4]  B. Phillips,et al.  Framework to help design and review research involving children , 2019, Archives of Disease in Childhood.

[5]  C. Tuleu,et al.  EPTRI – European Paediatric Translational Research Infrastructure. Bridging the gaps of the paediatric excellence medicine , 2019, British Journal of Pharmacy.

[6]  B. Phillips,et al.  How to involve children and young people in what is, after all, their research , 2019, Archives of Disease in Childhood.

[7]  B. Phillips,et al.  Making research central to good paediatric practice , 2019, Archives of Disease in Childhood.

[8]  G. Kearns,et al.  Developmental Changes in Pharmacokinetics and Pharmacodynamics , 2018, Journal of clinical pharmacology.

[9]  A. Saint‐Raymond,et al.  Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation , 2017, Pediatric Drugs.

[10]  Catriona Manville,et al.  The National Institute for Health Research at 10 Years: An Impact Synthesis: 100 Impact Case Studies. , 2016, Rand health quarterly.

[11]  B. Carleton,et al.  Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine , 2016, Pediatric Drugs.

[12]  L. Dimeglio,et al.  Special article: 2014 Pediatric Clinical Trials Forum , 2016, Pediatric Research.

[13]  C. Giaquinto,et al.  Successful private–public funding of paediatric medicines research: lessons from the EU programme to fund research into off-patent medicines , 2014, European Journal of Pediatrics.

[14]  J. Karres,et al.  Juvenile animal studies and pediatric drug development: a European regulatory perspective. , 2011, Birth defects research. Part B, Developmental and reproductive toxicology.

[15]  E. Napoleone Excellence in Family Paediatricians: the FIMP-MCRN (Medicines for Children Research Network) becomes a member of ENPR-EMA (European Network of Paediatric Research at the European Medicines Agency) , 2011, Italian journal of pediatrics.

[16]  崎山美知代 有効性に関するトピックの動向 ICH E11‐Addendum(R1):Clinical Investigation of Medicinal Products in the Pediatric Population Lisbon2016EWG会議の報告 , 2017 .

[17]  M. Schrappe,et al.  Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer. , 2015, European journal of cancer.

[18]  Ritu Sadana,et al.  Knowledge for better health: a conceptual framework and foundation for health research systems. , 2003, Bulletin of the World Health Organization.